Ritlecitinib
- Generic Name
- Ritlecitinib
- Brand Names
- Litfulo
- Drug Type
- Small Molecule
- Chemical Formula
- C15H19N5O
- CAS Number
- 1792180-81-4
- Unique Ingredient Identifier
- 2OYE00PC25
- Background
Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. In June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older. It was further approved by the EMA in September 2023. Ritlecit...
- Indication
Ritlecitinib is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older. It is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.
- Associated Conditions
- Severe Alopecia Areata (AA)
- Associated Therapies
- -
Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05636293
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT05583526
- Locations
- 🇨🇦
Whitby Health Centre Dermatology trials, Whitby, Ontario, Canada
🇨🇦Whitby Health Centre, Whitby, Ontario, Canada
🇨🇦Centre de Recherche Dermatologique du Quebec metropolitain, Quebec, Canada
Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)
- Conditions
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05522556
Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05097716
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05040295
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.